QUICK ANSWER · AEO / GEO
A copper-binding tripeptide with route-specific evidence; topical cosmetic research does not establish injectable systemic benefit.
ENTITY FACTS
What should readers identify first?
What remains unknown?
- clinical benefit and long-term safety of injectable GHK-Cu
- whether results from an older topical ulcer gel replicate in modern confirmatory trials
- optimal and safe formulation for each topical indication without extrapolating dose or route
- clinical relevance of collagen, gene-expression and matrix biomarkers
- results of Phase 2 NCT07437586, which has no posted results
- outcome of the planned FDA PCAC review before the end of February 2027; date and location remained unscheduled on 23 August 2026
What limits these conclusions?
- The human literature is small, old or formulation-specific. One controlled ulcer study has a positive abstract but does not report the total sample size there; the post-laser study had only 13 completers and no significant objective benefit. Cosmetic studies often use multiple ingredients and surrogate appearance endpoints. Preclinical mechanisms do not establish clinical outcomes, and topical evidence cannot be transferred to injection or systemic use.
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
- https://www.fda.gov/media/94155/download
- https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee
- https://www.fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs
- https://clinicaltrials.gov/study/NCT07437586
- https://pubmed.ncbi.nlm.nih.gov/17147644/
- https://pubmed.ncbi.nlm.nih.gov/16847171/
- https://pubmed.ncbi.nlm.nih.gov/11121126/
- https://pubmed.ncbi.nlm.nih.gov/11045606/
- https://single-market-economy.ec.europa.eu/sectors/cosmetics/cosmetic-ingredient-database/cosing-glossary-ingredients_en
- https://products.mhra.gov.uk/
FAQ · ANSWER ENGINE
Frequently asked questions
What is GHK-Cu?
GHK-Cu is described pharmacologically as Copper(II)-binding tripeptide complex / tissue-remodelling research. A copper-binding tripeptide with route-specific evidence; topical cosmetic research does not establish injectable systemic benefit.
Does GHK-Cu have strong evidence?
PrimeCoreBio records Evidence Grade C. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is GHK-Cu approved everywhere?
No global conclusion should be inferred. PrimeCore Class C must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.